PMV Pharmaceuticals, Inc.
PMVP· Nasdaq
PMVPPMV Pharmaceuticals, Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001193125-26-350448
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$18.09M | -$21.21M | -$1.21M | -$17.44M |
| EPS Diluted | -$0.34 | -$0.41 | -$0.02 | -$0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
PMV Pharmaceuticals, Inc. · CIK 1699382 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
